Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives

Abstract

This invention provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the invention is concerned with azaindoleoxoacetyl piperazine derivatives. These compounds possess unique antiviral activity, whether used alone or in combination with other antivirals, antiinfectives, immunomodulators or HIV entry inhibitors. More particularly, the present invention relates to the treatment of HIV and AIDS.

Description

REFERENCE TO RELATED APPLICATIONS[0001] This Continuation in Part application claims the benefit of U.S. Ser. No. 10 / 214,982 filed Aug. 7, 2002 which claims the benefit of U.S. Ser. No. 10 / 038,306 filed Jan. 2, 2002 and U.S. Provisional Application Serial No. 60 / 314,406 filed Aug. 23, 2001 and Ser. No. 60 / 266,183 filed Feb. 2, 2001.[0002] 1. Field of the Invention[0003] This invention provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the invention is concerned with azaindole piperazine diamide derivatives that possess unique antiviral activity. More particularly, the present invention relates to compounds useful for the treatment of HIV and AIDS.[0004] 2. Background Art[0005] HIV-1 (human immunodeficiency virus-1) infection remains a major medical problem, with an estimated 42 million people infected worldwide at the end of 2002. The number of cases of HIV and AIDS (acquired immunodeficiency syndrome) has...

AI Technical Summary

Benefits of technology

0116] The present invention comprises compounds of Formula I, or pharmaceutically acceptab

Problems solved by technology

HIV-1 (human immunodeficiency virus-1) infection remains a major medical problem, with an estimated 42 million people infected worldwide at the end of 2002.

Each of these drugs can only transiently restrain viral replication if used alone.

However, when used in combination, these drugs have a profound effect on viremia and disease progression.

However, despite these impressive results, 30 to 50% of patients ultimately fail combination drug therapies.

Furthermore, the high replication rate and rapid turnover of HIV-1 combined with the frequent incorporation of mutations, leads to the appearance of drug-resistant variants and treatment failures when sub-optimal drug concentrations are present (Larder and Kemp; Gulick; Kuritzkes; Morris-Jones et al; Schinazi et al; Vacca and Condra; Flexner; Berkhout and Ren et al; (Ref. 6-14)).

However, the major drawback to the development and application of NNRTIs is the propensity for rapid emergence of drug resistant strains, both in tissue cell culture and in treated individuals, particularly those subject to monotherapy.

However, these structures differ from those claimed herein in that they are aza-indole mono-amide rather than unsymmetrical aza-indole piperazine diamide derivatives, and there is no mention of the use of these compounds for treating viral infections, particularly HIV.

Images